Please select the option that best describes you:
Would you offer adjuvant chemotherapy for platinum eligible patients with pT2pN0 urothelial carcinoma of bladder or UTUC who did not receive neoadjuvant chemotherapy?
If so, what regimen would you use? Would a carboplatin-based regimen be acceptable or only cisplatin?
Answer from: Medical Oncologist at Academic Institution
In my practice, I'd offer both, but I'd recommend trial if it is availableIf there is no trial: I would say "yes" for upper tract urothelial carcinoma (UTUC). I routinely discuss and recommend adjuvant therapy based on the POUT study It showed the benefit of adjuvant therapy with platinum and ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I agree with both of my colleagues that adjuvant cisplatin-based combination chemotherapy is unproven for pT2N0 bladder cancer, although the POUT upper tract urothelial carcinoma phase III trial (which demonstrated significantly improved DFS) did recruit >=pT2N0 patients to evaluate adjuvant gemc...
Comments
Medical Oncologist at Virginia Cancer Spclsts PC
Would you use a carbo regimen if the patient is no...
Would you use a carbo regimen if the patient is no...
Medical Oncologist at University of Alabama School of Medicine
I agree with my esteemed colleagues above that I w...
I agree with my esteemed colleagues above that I w...
Answer from: Medical Oncologist at Academic Institution
In the setting of urothelial carcinoma of the upper tract including the renal pelvis and/or ureter, the POUT trial (The Lancet 2020), a phase 3 randomized controlled trial evaluating adjuvant chemotherapy with 4 cycles of either gemcitabine with cisplatin or carboplatin as compared to surveillance i...